/
Our common stock is listed on The Nasdaq Stock Market LLC ( Nasdaq ) under the symbol NEO. Overview NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology.
$7.91
$0.27 (-3.30%)
Price from 43 days ago
The business is unprofitable at the operating level (-15.93% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 10.1%, still solid.
Negative free cash flow of -$22M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$746M
▲ +10.1% YoY
Net Income (TTM)
-$99M
▼ -37.2% YoY
Op. Margin
-14.25%
▼ -2.0pp YoY
ROIC
-6.72%
▼ -1.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$5M
▲ +36.0% YoY
Op. Cash Flow (TTM)
$22M
▼ -25.5% YoY
Net Debt
$262M
Cash & Equiv.
$146M
5Y CAGR: +10.4%
Continue Research